Therapy for benign prostatic hyperplasia has evolved rapidly over the last decade, with the introduction in the early 1990s of new agents such as a 1 -blockers and 5a-reductase inhibitors. The major advantage of a 1 -blockers over 5a-reductase inhibitors is their rapid onset of action. Maximum¯ow rate is improved after ®rst administration and optimal symptom relief is usually reached within 2 ± 3 months. In addition, a 1 -blockers are effective regardless of prostate size and they provide a similar degree of symptom relief in patients with or without bladder outlet obstruction. The main adverse events with the a 1 -blockers relate to their effects on the cardiovascular system (postural hypotension) and central penetration (asthenia, somnolence). Newer uroselective a 1 -blockers, such as alfuzosin and tamsulosin, have a better safety pro®le and, as such, do not require initial dose titration. Alfuzosin has also been shown in a sixmonth study to signi®cantly reduce both residual urine and the incidence of acute urinary retention (AUR) compared with placebo. In addition, alfuzosin is effective in improving the success rate of a trial without catheter in patients with AUR.
Management of BPH
Therapy for benign prostatic hyperplasia (BPH) has evolved considerably over the past century. Performance of open prostatectomy, routine until 20 ± 25 years ago, has been gradually replaced by transurethral resection of the prostate (TURP), which is now the preferred surgical procedure worldwide. At the start of the 1990s, new therapies which were less interventional than TURP were introduced, such as thermotherapy, laser therapy and therapies involving radiofrequencies, e.g. transurethral needle ablation. To date, most of these techniques are still regarded as investigational and additional randomized studies focusing on costs and durability of symptomatic improvement are needed.
The development of medical therapy for BPH has been a long process, beginning with phytotherapy in Egyptian times. In the mid-1970s, the better understanding of the pathophysiology of BPH led to the ®rst use of phenoxybenzamine, an irreversible antagonist of both a 1 /a 2 adrenoceptors. Medical management of BPH suddenly exploded at the beginning of the 1990s with the introduction of selective a 1 -blockers and 5a-reductase inhibitors.
In terms of treatment goals for BPH, the two main objectives are to reduce symptoms and relieve obstruction. Obstruction and symptoms are not correlated, however, and patients may present with signi®cant symptoms but no obstruction. Consequently, it is important to distinguish between different patient types in order that the most appropriate treatment be given.
TURP
Dramatic reduction in the use of TURP for the treatment of BPH worldwide have been reported, with perhaps the greatest decline in number of procedures being noted in the US (Figure 1 ). 1 TURP constituted 94% of all BPH surgery in 1995 in the US, but has declined to 52% over the past decade. 2 Only in the UK, where the number of procedures has been consistently low, has the incidence not declined appreciatively. TURP is often referred to as the gold standard treatment for BPH, but in actual fact it is not the ®rst treatment choice for the majority of patients. Recent experience in clinical practice has shown that many patients prefer less aggressive interven-tions than TURP, even if their symptoms are relatively severe. 3 Surgery for BPH remains mandatory, however, for a number of conditions, including: refractory urinary retention (after at least one attempt to remove the catheter), recurrent urinary tract infection due to benign prostatic obstruction (BPO), recurrent gross haematuria due to benign prostatic enlargement (BPE), bladder stones, large bladder diverticula, and renal failure due to BPO. 4 In terms of improvement in symptoms,¯ow rate and obstruction, TURP is the standard against which other therapies should be compared. However, it is associated with a low, but signi®cant morbidity, even when performed by experienced urologists. In particular, sexual function appears to be a major area of concern, with retrograde ejaculation occurring in nearly 75% of patients and about 15% of potent men becoming impotent. 5 
Medical therapy
Concurrently with the decline of surgery, the total market for medical therapies for BPH has considerably increased over the past nine years worldwide, mainly due to the emergence of two classes of medications, a 1 -blockers and 5a-reductase inhibitors. These agents have unambiguously demonstrated their ef®cacy and good safety pro®le in well-designed, placebo-controlled studies. Surprisingly, despite the lack of long-term data con®rming their ef®-cacy, sales of phytotherapeutic agents (expressed in millions of treatment days) have remained stable for a number of years and are just starting to decline ( Figure  2 ). While the market for 5a-reductase inhibitors has been stable since 1995, that of a 1 -blockers is expanding rapidly worldwide. a 1 -blockers and 5a-reductase inhibitors have very different modes of action. The former targets the dynamic component of bladder outlet obstruction (BOO), by decreasing the sympathetically controlled tone of prostatic, urethral and bladder neck smooth muscle, whilst the latter targets the static component, i.e. prostate gland size. The choice between these two treatment options implies a critical analysis of various parameters, such as the rapidity of action, the magnitude of the symptom relief, the safety pro®le and also the long-term outcome (Table 1) .
Rapid onset of action
While the 5a-reductase inhibitor ®nasteride may take three to six months to be effective, there is no doubt that the principal advantage of a 1 -blockers is their rapid onset of action. Hence, alfuzosin has been shown to increase maximum¯ow rate (Q max ) by about 30% from the ®rst administration, 6 which represents the bene®t expected from an a 1 -blocker in the medium and long term. Lower urinary tract symptoms (LUTS) improvement is also rapid and reaches its maximum within two to three months of treatment. 7 ± 10 Overall, the magnitude of symptom relief is very similar with different a 1 -blockers. 11 
Effect on obstruction
Limited studies are available examining the effect of a 1 -blockers on BOO. Two placebo-controlled studies have been conducted examining the effect of a 1 -blockers on detrusor pressure at Q max , the single measurement most closely associated with the presence and degree of BOO. A study by Martorana et al 12 showed that after four weeks of treatment with alfuzosin (7.5 mg/day), detrusor pressure at Q max decreased from 78 cmH 2 15 respectively; however, neither study had a placebo control. These results suggest that a 1 -blockers have a moderate but bene®cial effect on obstruction, although there is increasing evidence that a 1 -blockers provide a similar improvement in LUTS and quality of life in those patients with and without BOO. 14 a 1 -Blocker plus ®nasteride combination studies
In the early 1990s, there was much debate on the potential therapeutic bene®ts of combining two medical therapies with very different modes of action, i.e. an a 1 -blocker and ®nasteride. Both drugs are capable of improving LUTS and Q max and their effect may, in theory, be synergistic. The value of the combination has now been tested up to one year in three major studies involving terazosin/ ®nasteride, 9 alfuzosin/®nasteride 16 and doxazosin/®nas-teride. 17 However, none of these studies demonstrated any added bene®t of combining the two types of drug.
In the ®rst combination study, the Veterans' Affairs (VA) Study, the safety and ef®cacy of terazosin (10 mg/ day), ®nasteride (5 mg/day), the combination of the two and placebo were compared in 1229 men with BPH over a one-year period. 9 The mean changes in I-PSS at one year were of the same order of magnitude with terazosin (À6.1) and the combination (À6.2), both being signi®-cantly higher than ®nasteride (À3.2) and placebo (À2.6). Similarly, mean increases in Q max at one year were signi®cantly higher with terazosin ( 2.7 mL/s) and the combination ( 3.2 mL/s) than with ®nasteride ( 1.6 mL/s) and placebo ( 1.4 mL/s).
The second combination study, the ALFIN Study, compared alfuzosin (10 mg/day), ®nasteride (5 mg/ day), and the combination of the two in 1051 patients with BPH over a six-month period. 16 Mean changes in I-PSS were signi®cantly higher with alfuzosin, alone (À6.3) Figure 2 Worldwide trends in medical therapy for benign prostatic hyperplasia. From IMS Health Retail Data.
a a 1 -Blocker therapy K Ho Èfner or in combination (À6.1), than with ®nasteride (À5.2). In those patients likely to be obstructed, increases in Q max were also signi®cantly higher with alfuzosin ( 2.9 mL/s) and the combination ( 2.9 mL/s) than with ®nasteride alone ( 2.1 mL/s; P`0.02).
Results of a third combination study (PREDICT) comparing doxazosin (8 mg/day), ®nasteride (5 mg/day), the combination of two and placebo in 1089 BPH patients, further con®rm the VA Study and ALFIN results. Over a one-year treatment period, improvement in LUTS and Q max were signi®cantly higher with doxazosin and the combination, as compared with ®nasteride alone and placebo, with no additional bene®t of the combination. 17 Unlike ®nasteride, which has been shown to offer greater bene®ts in prostates greater than 40 mL, 18 prostate size does not in¯uence the ef®cacy of a-blockers in BPH. 19 For this reason, one criticism of the VA Study was the inclusion of men with small prostates (mean prostate volumes at baseline ranged from 36 ± 38 mL). However, it is interesting to note that in both the ALFIN (Figure 3 ) and PREDICT Studies, 17 prostate size clearly did not in¯uence the results; the a 1 -blocker was more effective than ®nasteride even in patients with enlarged prostates.
Whether the results would have been different in very long-term comparative studies needs to be demonstrated.
Side effects
Since the research on the ®rst a-adrenoceptor antagonist, phenoxybenzamine, in the mid-1970s, more selective antagonists which bind speci®cally to the a 1 -adrenoceptors, the prime determinants of human prostatic smooth muscle contraction, have been identi®ed. 20 However, none of the a 1 -blockers speci®cally target the prostate and potential adverse events with this group of drugs relate mainly to their effects on the cardiovascular system, e.g. dizziness, headache, postural hypotension and syncope. Blood ± brain barrier penetration can also lead to central events, such as asthenia and somnolence. Orthostatic hypotension, occurring mainly at the ®rst administration of the compound, is a particular cause of concern, as it may result in substantial morbidity and mortality from associated falls and syncope, especially in elderly patients. 21 For this reason, most currently available a 1 -blockers such as prazosin, terazosin and doxazosin need to be started at low dose in order to avoid a`®rst dose phenomenon' and titrated to obtain maximum ef®cacy and tolerability. Despite initial dose titration precautions, the ®rst dose phenomenon can also occur in those patients with irregular compliance.
The risks associated with the use of a 1 -blockers have been demonstrated in the VA Study: 9 postural hypotension was shown to be four times more frequent in patients who received terazosin than in those who received placebo or ®nasteride; dizziness was three times more frequent and asthenia twice as frequent (Figure 4a ). By comparison, new uroselective a 1 -blockers such as alfuzosin and tamsulosin, administered without dose-titration in randomized clinical trials, clearly offer a better safety pro®le. This was demonstrated in the ALFIN Study, where the incidence of postural hypotension, asthenia and dizziness with the sustained-release formulation of alfuzosin, alone or in combination, was low and similar to that observed in patients treated with ®nasteride, which is completely devoid of cardiovascular effects (Figure 4a ). 16 The safety pro®le of tamsulosin which shows a slight a 1A selectivity is, in fact, very similar to that of alfuzosin as shown by a randomized study directly comparing both drugs. 22 The decrease in blood pressure was slightly more pronounced with alfuzosin (immediate-release formulation), but this had no in¯uence on the rate of drop-outs for adverse events (alfuzosin 4% vs tamsulosin 8%) or the incidence of postural hypotension (alfuzosin 1% vs tamsulosin 3%).
Compared with 5a-reductase inhibitors, a 1 -blockers also have an advantage with respect to sexual function and this needs to be taken into account in sexually active patients. Hence, in both the VA and ALFIN Studies, erectile dysfunction, ejaculatory abnormality and decreased libido were more frequently reported in patients treated with ®nasteride or the combination therapy (Figure 4b) . 9, 16 Interestingly, a high rate of abnormal ejaculation has recently been reported with the a 1 -blocker, tamsulosin. In a 53-week study conducted in the US, a dose ± response effect was recorded; abnormal ejaculation occurred in 26% of patients treated with 0.8 mg tamsulosin and 10% of patients treated with a 0.4 mg dose of the drug. 8 This compares with 0% of patients in the placebo group. Incidence of abnormal ejaculation in a European study published by Chapple and co-workers 23 was lower at 4.5% with tamsulosin (0.4 mg), compared with a 1% incidence in the placebo group, but the duration of this study was only 12 weeks. As none of the 1544 patients treated with alfuzosin in randomized controlled studies reported abnormal ejaculation, 24 it has been suggested that this effect may be due to the speci®c selectivity of tamsulosin for the a 1A -adrenoceptor subtype. However, this needs to be con®rmed.
Bene®ts of a a 1 -blockers on acute urinary retention
Acute urinary retention (AUR) is one of the main complications of BPH and represents a mandatory indication for surgery in case of recurrence. Large community-based studies have contributed to identifying risk factors for AUR, such as increasing age, severity of symptoms, low Q max , enlarged prostate and abnormal residual urine. 25 ± 27 Recent data suggest that 5a-reductase inhibitors are associated with a lower incidence of AUR compared with placebo in the long-term. 28 a 1 -Blockers, by reducing sympathetic overstimulation, i.e. the main pathophysiologic Figure 4 Comparative safety pro®le in ALFIN 16 and VA Studies. 9 (a) Side effects possibly related to vasodilation. Global P values for VA Study: postural hypotension, P`0.001; asthenia, P 0.02; dizziness, P`0.001. Global P values for ALFIN Study: postural hypotension, ns; asthenia, ns; dizziness, ns. (b) Side effects possibly related to sexual function. Global P values for VA Study: ejaculatory abnormality, P`0.001; decreased libido, P 0.05; impotence, P 0.05. Global P values for ALFIN Study; ejaculatory abnormality, P 0.04; decreased libido, ns; impotence, P`0.002. mechanism of AUR, 29 have also shown a bene®cial impact on this complication. Hence, alfuzosin has been demonstrated in a large placebo-controlled study involving 518 patients, to reduce signi®cantly post-void residual urine as well as the incidence of AUR: over a sixmonth period, AUR occurred in one patient (0.4%) in the alfuzosin group and seven patients (2.6%; P 0.04) in the placebo group. 30 This bene®t has been con®rmed in the three-year open study in 3228 patients in general practice, in which the incidence of AUR was only 0.3%. 31 Although there was no placebo arm, the incidence of AUR in this study was lower than the 2 ± 3% incidence reported in the literature for watchful waiting. 32 Alfuzosin has also been shown to favour return to a normal voiding pattern in a trial without catheter (TWOC) conducted in BPH patients with AUR. 33 Alfuzosin was given at a dose of 5 mg twice daily in the 24-h period before catheter removal and for 24 h following removal. A failed TWOC was de®ned as recatheterisation within 24 h of removal due to a further episode of AUR or because the patient was passing small urine volumes. Results showed that 55% of patients treated with alfuzosin voided successfully after catheter removal compared with 29% of patients receiving placebo (P 0.03).
Conclusion
Since the early 1990s there has been a shift in the management of BPH away from surgical intervention towards medical therapy. The ®rst-line medical treatment option for patients with LUTS suggestive of BPH is a 1 -blocker therapy. These agents provide rapid and effective relief of symptoms, as well as providing long-term bene®ts in reducing the risk of AUR. In addition, a-blockers are not affected by prostate size and have a good safety pro®le. Improvements in patient selection for the appropriate treatment are still needed, however, to determine which patients can bene®t from the less invasive therapeutic options.
